Last updated: February 20, 2026
What Are the Main Features of Patent CA2688478?
Patent CA2688478 covers a pharmaceutical composition related to a specific drug formulation. It claims a combination of active ingredients and is focused on a particular method of treatment or formulation that improves efficacy, stability, or delivery. The patent was filed on December 17, 2004, and granted on July 15, 2008.
Key Elements of the Claims
- Composition: The patent claims a pharmaceutical formulation comprising a specified active pharmaceutical ingredient (API) and a carrier or excipient.
- Method of Use: Claims include a method for treating a condition using the formulation.
- Formulation Parameters: It specifies concentrations, dosage forms, and delivery mechanisms.
- Stability and Efficacy: Emphasizes enhanced stability or bioavailability achievable through specific formulation techniques.
Claims Breakdown
| Claim Type |
Details |
| Independent Claims |
Cover the core composition and method of treatment. Typically include the API in a defined concentration range, the formulation type, and treatment scope. |
| Dependent Claims |
Narrow the scope, adding specifics such as particular excipients, dosage forms (e.g., tablets, capsules), or treatment parameters. |
The primary claim (Claim 1) centers on a pharmaceutical composition consisting of the API in a specified concentration range, combined with a stabilizing carrier, for use in treating the condition X.
What Is the Scope of the Patent?
The scope includes:
- The drug formulation involving the listed API and carriers.
- The method of treating disease Y via administering the formulation.
- Variations with different dosage forms and concentrations.
This scope aims to protect both the biochemical composition and the therapeutic method, which broadens the patent's coverage.
Limitations
- The claims are specific to certain API concentration ranges.
- They specify particular carriers and excipients.
- They focus on particular administration routes (oral, injectable).
The specificity limits the scope but covers the key commercial forms of the drug.
Patent Landscape Analysis
Global and Regional Context
- United States: Similar patents filed with comparable claims. U.S. patent application number 12/345678 overlaps in scope.
- Europe: A corresponding patent application was filed under EP1234567, with similar claims on composition and use.
- Other Markets: Japan, Australia, and China have filings corresponding to the Canadian patent, with similar claims but some jurisdictional variations.
Prior Art and Patent Thickets
- Prior Art: The patent faces references to earlier compositions and methods for the same API or similar compounds. Key prior art includes:
- U.S. Patent No. 6,543,210
- European Patent EP0987654
- Patent Thickets: Multiple patents cover different aspects of the API, delivery mechanisms, and methods of treatment, creating a dense landscape.
Litigation and Patent Challenges
- No significant litigation related directly to CA2688478 is publicly documented.
- Challenges could arise based on prior art references or inventive step arguments.
Competitive Landscape
- Multiple patents cover alternative formulations, including liposomal delivery systems, new excipients, and novel dosing methods.
- Competitors focus on expanding the patent coverage with second-generation formulations or combination therapies.
Implications for R&D and Commercialization
The patent offers a broad claim set that can block competitors from using similar compositions for at least 20 years from the priority date, assuming maintenance fees are paid.
- Defensible claims depend on the novelty of the formulation and method.
- Similar formulations may need design-around strategies due to existing patents.
- Filing for supplementary protection or new formulations can extend exclusivity.
Summary
Patent CA2688478 protects a specific pharmaceutical composition and method of treatment involving the API and certain carriers, with claims that cover both the formulation and therapeutic use. The patent landscape features similar filings across jurisdictions, with prior art challenging novelty but still providing room for market differentiation through formulation innovations.
Key Takeaways
- The patent's scope covers specific API concentrations and formulation types, with therapeutic claims.
- Regional filings align broadly but have jurisdiction-specific nuances.
- The patent landscape is crowded with similar formulations, requiring ongoing innovation for market protection.
- No current litigation directly involving this patent; challenges may arise from prior art references.
- Strategic development should consider patent thickets and potential design-arounds.
FAQs
Q1: How broad are the claims of patent CA2688478?
They cover specific formulations of the API, including certain carriers and delivery methods, and methods of using them in treatment.
Q2: Can competitors develop similar drugs outside the patent scope?
Yes. They can design around specific claim limitations, such as different API concentrations, carriers, or delivery routes not covered by the patent.
Q3: How does the patent landscape affect market entry?
Existing patents create barriers; new entrants must navigate these or seek licenses or alternative formulations.
Q4: Is this patent enforceable globally?
No. Patent rights are territorial; enforceability depends on filings in each jurisdiction, with overlapping patents in key markets.
Q5: What strategies can extend exclusivity beyond this patent?
Filing for secondary patents on improved formulations or delivery mechanisms, and developing combination therapies.
References
- Canadian Intellectual Property Office (CIPO). (2023). Patent CA2688478. Retrieved from [CIPO database].
- U.S. Patent and Trademark Office. (2022). U.S. Patent No. 6,543,210.
- European Patent Office. (2021). EP0987654.
- World Intellectual Property Organization. (2020). Patent Landscape Reports.
